Correction to *Lancet Oncol* 2016; 17: 1590–98

Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol *2016; **17:** 1590–98*—In this Article, the declaration of interests should read "PSh has received fees for advisory board participation for Jounce and Kite; fees for consultancy from Jounce, Kite, Bristol-Myers Squibb, AstraZeneca, and Amgen; and stock or stock options from Jounce and Kite. MKC has received grants from Bristol-Myers Squibb; consultancy fees from AstraZeneca and Moderna; and payment for lectures from Clinical Care Options. PB has received honoraria from Bristol-Myers Squibb, Pfizer, MSD, and Orion Pharma, and research funding from Novartis. JK has received research funding from Immune Design; and consultancy fees from Valeant Pharmaceutical, Voluntis, and Genentech/Roche. ECa reports research grants and/or financial support from Boehringer Ingelheim, Roche/Genentech, Bristol-Myers Squibb, Novartis, PsiOxus, Nanobiotix Janssen, AbbVie, PharmaMar, PUMA, Sanofi, Lilly, Pfizer, Merck, Nektar, Amcure, Amgen, AstraZeneca, Principia, Bayer, CytomX, H3, Incyte, Kura, LOXO, Macrogenics, Menarini, Merck Serono, Merus, Millenium, Rigontec, Tahio, and BeuGene Tesaro; consultancy fees from Janssen-Cilag, Alkermes (and travel expenses), Seattle Genetics, Pierre Fabre, Cerulean Pharma, EUSA, Celgene, Novartis (speakers' bureau), Nanobiotix, PsiOxus Therapeutics, AbbVie, AstraZeneca, Guidepoint Global, Roche/Genentech (and travel expeneses), GLG, Pfizer, Servier, Amcure, and Boehringer Ingelheim; ownership from START (leadership), Oncoarts Associated and International Cancer Consultants; and employment from START and HM Hospitals Group (honoraria) and president and founder of NPO Foundation Intheos (Investigational Therapeutics in Oncological Sciences), outside the submitted work. RNP has received a travel grant from Bristol-Myers Squibb for an investigator meeting. PAO has received a grant from Bristol-Myers Squibb and consultancy fees from Bristol-Myers Squibb, Amgen, Celldex, Alexion, and Cytomx. FdB has received consultancy fees from Tiziana Life Sciences, Bristol-Myers Squibb, MSD, Servier, Eli Lilly, Merck Serono, GlaxoSmithKline, and Novartis, and speaker fees from Bristol-Myers Squibb, Eli Lilly, Roche, and ACCMED. MM has received consultancy fees from Etubics and Boehringer Ingelheim, and speaker fees from Genentech, Novartis, Sanofi, Regeneron, Lexicon, Ipsen, Onyx, Bayer, Taiho, Merrimack, and Celgene. AA is an employee of Bristol-Myers Squibb. DJ has received consulting fees from Definiens, F Hoffmann-La Roche, CureVac, Roche Pharma, Novartis Pharma, and Novartis Oncology-Novartis Farma, outside the submitted work; and has a patent issued for intellectual property of infiltrating T-cell density predicting outcome. ECh has received grants from Bristol-Myers Squibb and consultancy fees for advisory board participation from EMD Serono, Taiho, Bayer, Advaxis, Amgen, Lilly, and Castle Biosciences. CH, C-SL, and MT are employees of and hold stock options with Bristol-Myers Squibb. JER has received grants for study conduct from Novartis; funds for clinical trial conduct from Astellas, Seattle Genetics, Bayer, AstraZeneca, Mirati Therapeutics, Oncogenex, and Roche/Genentech; has received consultancy fees from Roche/Genentech, AstraZeneca, Eli Lilly, Astellas, Seattle Genetics, Bristol-Myers Squibb, Merck, EMD-Serono, Adicet Bio, western oncolytics, Pharmacyclics, Sensei Biotherapeutics, Bayer, BioClin Therapeutics, QED Therapeutics, Mirati Therapeutics, Fortress Biotech, Gritstone Oncology, Inovio; has received honoraria from Bristol-Myers Squibb and Chugai; has held stock in Illumina and Merck. PSp and DTL declare no competing interests." This correction has been made to the online version as of Feb 1, 2019.

Correction to *Lancet Oncol* 2017; 18: 904–16

Baselga J, Im S-A, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol *2017; **18:** 904–16*—In this Article, the declaration of interests should read "JB has received reimbursement for travel, and advisory board and consulting fees from Novartis, during the conduct of the study; has received personal fees and held stock as a member of the board of directors from Aura Biosciences; has received personal fees as a member of the advisory board and held stock as a founder of Northern Biologics (f/k/a Mosaic Biomedicals); has received personal fees and held stock as a member of the board of directors from Infinity Pharmaceuticals; held stock as a member of the advisory board from ApoGen Biotechnologies; has received personal fees and held stock as a member of the advisory board from PMV Pharma; has received personal fees and held stock as a member of the advisory board from Juno Therapeutics; has received personal fees and held stock as co-founder from TANGO (f/k/a Synthetic Lethal); has received personal fees and held stock as a member of the scientific advisory board and the board of directors from GRAIL; has received personal fees and held stock as a member of board of directors from Varian Medical Systems; held stock as a member of board of directors from Foghorn Therapeutics; has received reimbursement for travel,

and advisory board and consulting fees from Eli Lilly; has received personal fees and held stock as a member of advisory board from Seragon; has received reimbursement for travel and in-kind items and services from Roche, outside the submitted work. S-AI reports grant support from AstraZeneca and advisory consultant roles for AstraZeneca, Eisai, Novartis, Pfizer, Roche/Genentech and Spectrum, outside the submitted work. HI reports grant support and personal fees from Novartis during the conduct of the study; HI was also an uncompensated member of the steering committee of this study; HI has received personal fees in the form of honoraria and consulting fees from AstraZeneca, Pfizer, Lilly, Daiichi-Sankyo, and F Hoffman La-Roche via Chugai, outside the submitted work. JC reports personal fees from Novartis, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceuticals, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Pfizer, Eisai, and Samsung; has received stock, patents, and intellectual property from MedSIR; has received personal fees and research funding to his institution from Roche, outside the submitted work. MDLs reports personal fees in the form of speaker's honoraria and advisory board honoraria from Novartis, Roche, Lilly, Pfizer, Eisai, Ipsen, and Teva, outside the submitted work. CLA reports personal fees for participation in a steering committee for the clinical trial from Novartis, during the conduct of the study; and personal fees for an expert advisory role from Eli Lilly, AstraZeneca, Genentech, Millennium, Celgene, Pfizer, Radius, and Merck, outside the submitted work. WJ reports personal fees from Novartis for the roles of lecturer and advisory board member, outside the submitted work. MC reports funding from Novartis to attend the IMPAKT meeting, outside the submitted work. YI reports grant support from Novartis, Chugai, Parexel, EPS, Daiichi Sankyo, MSD, AstraZeneca, and Lilly, during the conduct of the study. AA reports honorarium for advisory board from Novartis, Roche, Pfizer, and Puma, outside the submitted work. SC reports personal fees in the form of honorarium for advisory boards from Novartis during the conduct of the study. SC also reports personal fees received in the form of honoraria for advisory boards from Novartis, Hoffmann LaRoche, Pfizer, AstraZeneca, and Genomic Health; and institutional research support from Novartis, Hoffmann LaRoche, Pfizer, AstraZeneca, Genomic Health, Genentech, Merck, and BMS, outside the submitted work. BP reports institutional research funding from Merus, Puma, and Pfizer, and travel support from Pfizer and AstraZeneca, outside the submitted work. SH reports payment from Novartis to UCLA during the conduct of this study. She also reports grant support from Ambryx, Amgen, Bayer, OBI Pharma, Bimarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GSK, Lilly, Macrogenics, Medivation, Merrimack, Novartis, Pfizer, Pieris, Puma, Roche, Seattle Genetics, and travel support from Lilly, Novartis, and OBI Pharma, outside the submitted work. MT reports personal fees from AstraZeneca, Chugai, Kyowa Kirin, Novartis, Pfizer, and Eli Lilly, outside the submitted work. reports grant support from Novartis during the conduct of this study; he also reports personal fees for advisory board participation from Novartis, speaker's fees from Pfizer and AstraZeneca, and fees for advisory board participation and travel grants from Roche, outside the submitted work. PV reports grant support from Novartis during the conduct of this study; he also reports personal fees for advisory board participation from Novartis, speaker's fees from Pfizer and AstraZeneca, and fees for advisory board participation and travel grants from Roche, outside the submitted work. BD, SH, PU, and CM are employees of Novartis. EDiT reports personal fees as an employee of Novartis Pharmaceutical Corporation at the time of the study conduct and when the first draft of the manuscript was developed. MC reports grant support, personal fees and non-financial support from Novartis during the conduct of this study. He also reports grant support and personal fees from Roche and Pfizer, grant support from TESARO, and personal fees from AstraZeneca, outside the submitted work. All other authors declare no competing interests." This correction has been made to the online version as of Feb 1, 2019.

Correction to *Lancet Oncol* 2019; 20: 159–64

Wolf A, Naylor K, Tam M, et al. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study. Lancet Oncol *2019; **20:** 159–64*—In the Summary of this Article, the percentages for incidence rates and cumulative incidence have been corrected. These corrections have been made to the online version as of Feb 1, 2019.

Correction to *Lancet Oncol* 2019; 20: 179–80

Massari F, Di Nunno V. CheckMate 214 patient-reported outcomes: listening to our patients. Lancet Oncol *2019; **20;** 179–80*—In this Comment, the following sentence has been edited from "…time to deterioration in PRO scores was lower for patients who were given nivolumab plus ipilimumab…" to "…risk of deterioration in PRO scores was lower for patients who were given nivolumab plus ipilimumab…". This correction has been made to the online version as of Feb 1, 2019, and the printed version is correct.